Intratympanic injections of a steroid are an effective treatment for Ménière’s disease, according to the results of a study recent published in The Lancet.
Researchers from Imperial College London in the United Kingdom compared current treatments for Ménière’s disease. They found that intratympanic administration of the corticosteroid methylprednisolone is as effective as the current “gold standard” treatment of intratympanic gentamicin, but without the side effects associated with the latter. While gentamicin reduces vertigo, it can damage vestibular function and worsen hearing.
In the study, 256 patients with Ménière’s disease were screened between June 2009 and April 2013, 60 of whom were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone. In all 60 participants, the mean number of vertigo attacks in the final 6 months of the study period when compared with the 6 months before the first injection (primary outcome) decreased by 87% in the gentamicin group and by 90% in the methylprednisolone group.| | | Next → | Single Page